Correlation between Increased BMI, Metabolic Syndrome, and Benign Prostatic Hyperplasia in Young Obese Males: A Comprehensive Review
Published: 2024-07-11
Page: 52-58
Issue: 2024 - Volume 7 [Issue 1]
Yassir Jassim Mohammed Mohammed *
Canadian Specialist Hospital Dubai, United Arab Emirates.
*Author to whom correspondence should be addressed.
Abstract
Background: Benign prostatic hyperplasia is a prevalent condition affecting men, with risk factors such as age, lifestyle, inflammation, sex hormones, and genetics. However, the link between metabolic syndrome and BPH has gained attention, particularly among young, obese males under 40.
Literature Review: This review explores the incidence and impact of increased body mass index and metabolic syndrome in causing benign prostatic hyperplasia (BPH) in young, obese males, particularly those under 40 years old. The connection between BPH and MetS was first noted over twenty years ago by Hammarsten and colleagues, who found a direct correlation between Mets components and prostate volume. Subsequent studies in the United States and the United Kingdom corroborated these findings, showing that young males with three or more MetS components have a higher risk of developing BPH. Studies employing the American Urological Association Symptom Index indicated that men with mild lower urinary tract symptoms (LUTS) significantly increased MetS prevalence among men under 40 years old. Research in Asia has highlighted a growing incidence of LUTS, correlating with increased blood pressure, fasting blood glucose, and increased BMI. A meta-analysis found a 28% higher chance of developing BPH among men with higher BMI, and Obese persons were found to have a chance of having an enlarged prostate that was three and a half times higher than the average. Besides BMI, Various studies have examined other clinical markers associated with obesity, such as dyslipidemia and elevated serum insulin levels, which have been linked to increased prostate growth rates.
Conclusion: These findings underscore the need for further research to understand the mechanisms and address the disparities in BPH prevalence among different racial and ethnic groups. Addressing obesity and MetS through lifestyle modifications and medical interventions could potentially reduce BPH incidence in young, obese males.
Keywords: Benign prostate hyperplasia, metabolic syndrome, body mass index, BMI
How to Cite
References
Ngai HY, Yuen KS, Ng CM, Cheng CH, Chu SP. Metabolic syndrome and benign prostatic hyperplasia: An update. Asian J Urol. 2017;4(3):164-73.
Kaplan SA, Lee JY, Meehan AG, Kusek JW. Time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: The MTOPS trial. The Journal of Urology. 2016;195(6):1825-9.
Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian Journal of Urology. 2014;30(2):170-6.
Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: Definitions and controversies. BMC Medicine. 2011;9:1-13.
Mohammed Arafat, Heba, Nahed Ali Al Laham, Ohood Mohammed Shamallakh, and Kholoud Mohammed Shamallakh. Effect of Rotating Shift on Biomarkers of Metabolic Syndrome and Inflammation Among Health Personnel in Gaza Governorate. Journal of Advances in Medicine and Medical Research. 2021;33(24):43-59. Available:https://doi.org/10.9734/jammr/2021/v33i2431223
Altowerqi ZM, Zainuddin ZAB. Comparison of metabolic syndrome, uric acid and leisure time physical activity between former athletes and non-athlees. Journal of Pharmaceutical Research International. 2021;32(48):85–95.
DOI: 10.9734/jpri/2020/v32i4831128.
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: Prevalence and incident rates. Urologic Clinics. 2016;43(3):289-97.
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. European Urology. 2007;51(1):199-206.
Rył A, Rotter I, Miazgowski T, Słojewski M, Dołęgowska B, Lubkowska A, Laszczyńska M. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?. Diabetology & Metabolic Syndrome. 2015;7:1-7.
Meng J, Liu Y, Guan S-Y, Ma H, Zhang X, Fan S, et al. Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: Evidence from 5285 patients. International Journal of Clinical Practice. 2019;73(12):e13438.
Li B-H, Deng T, Huang Q, Zi H, Weng H, Zeng X-T. Body mass index and risk of prostate volume, international prostate symptom score, maximum urinary flow rate, and post-void residual in benign prostatic hyperplasia patients. American Journal of Men's Health. 2019;13(4):1557988319870382.
Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States. NCHS Data Brief. 2020;360:1-8.
Fowke JH, Koyama T, Fadare O, Clark PE. Does inflammation mediate the obesity and BPH relationship? An epidemiologic analysis of body composition and inflammatory markers in blood, urine, and prostate tissue, and the relationship with prostate enlargement and lower urinary tract symptoms. PloS One. 2016;11 (6):e0156918.
Li J, Peng L, Cao D, Gou H, Li Y, Wei Q. The association between metabolic syndrome and benign prostatic hyperplasia: A systematic review and meta-analysis. The Aging Male. 2020; 23(5):1388-99.
Wu S, He H, Wang Y, Xu R, Zhu B, Zhao X. Association between benign prostate hyperplasia and metabolic syndrome in men under 60 years old: A meta-analysis. Journal of International Medical Research. 2019;47(11): 5389-99.
Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. The Journal of Urology. 2009;182(2):616-25.
DiBello JR, Ioannou C, Rees J, Challacombe B, Maskell J, Choudhury N, et al. Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: A large, cross‐sectional, UK epidemiological study. BJU International. 2016;117(5):801-8.
Attia AAM, AbdElaal HM, Yasien HA, Elgharbawy MS. Correlation between metabolic syndrome and benign prostatic hyperplasia. Menoufia Medical Journal. 2021;34(1):43-6.
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. Jama. 2006;295(13):1549-55.
Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Current Prostate Reports. 2006;4(3):127-31.
Yoo S, Oh S, Park J, Cho SY, Cho MC, Jeong H, et al. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men. BJU International. 2019; 123(1):140-8.
Lemieux I, Després J-P. Metabolic syndrome: past, present and future. MDPI; 2020. p. 3501.
Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, et al. Metabolic syndrome and benign prostatic enlargement: A systematic review and meta‐analysis. BJU International. 2015;115(1):24-31.
Wang S, Mao Q, Lin Y, Wu J, Wang X, Zheng X, et al. Body mass index and risk of BPH: a meta-analysis. Prostate Cancer and Prostatic Diseases. 2012;15(3):265-72.
Batai K, Phung M, Bell R, Lwin A, Hynes KA, Price E, et al. Correlation between body mass index and prostate volume in benign prostatic hyperplasia patients undergoing holmium enucleation of the prostate surgery. BMC Urology. 2021;21(1):88.
Khan S, Wolin K, Pakpahan R, Grubb R, Colditz G, Ragard L, et al. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia. BMC Urology. 2021;21:1-13.
Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. The Lancet Healthy Longevity. 2022;3(11):e754- e76.
Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. American Journal of Epidemiology. 2003;157(10):906- 14.
Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 2006;91(7):2562-8.
Chen W, Man S, Wang B, Kadeerhan G, Huang X. Metabolically healthy obesity is associated with increased risk of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A cohort study of C hinese elderly males. LUTS: Lower Urinary Tract Symptoms. 2022; 14(3):170-7.
Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. European Urology. 2001;39(2):151-8.
Dahle SE, Chokkalingam AP, Gao Y-T, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. The Journal of Urology. 2002;168(2):599-604.
Cohen PG. Abdominal obesity and intra-abdominal pressure: A new paradigm for the pathogenesis of the hypogonadal-obesity-BPH-LUTS connection. Hormone Molecular Biology and Clinical Investigation. 2012;11(1):317-20.
Reaven G. The metabolic syndrome: time to get off the merry‐go‐round? Journal of Internal Medicine. 2011;269(2):127-36.
Duvnjak L, Duvnjak M. The metabolic syndrome-an ongoing story. J Physiol Pharmacol. 2009;60(Suppl 7):19-24.
Mondul AM, Giovannucci E, Platz EA. A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. The Journal of Urology. 2014;191(3):715-21.
Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Tubaro A, Vignozzi L, et al. Central obesity is predictive of persistent storage lower urinary tract symptoms (LUTS) after surgery for benign prostatic enlargement: Results of a multicentre prospective study. BJU international. 2015;116(2):271-7.